RECRUITING

Deep TMS of Neural Circuits Associated With Stimulant Use Disorder

Conditions

Methamphetamine Use Disorder Transcranial Magnetic Stimulation Veterans Deep Transcranial Magnetic Stimulation (dTMS)Neuroimaging Relapse

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study aims to evaluate the efficacy of deep transcranial magnetic stimulation (dTMS) as a treatment for Veterans with a methamphetamine use disorder (MUD).

Official Title

Deep TMS Neuromodulation of Neural Circuits Associated With Stimulant Use Disorder

Quick Facts

Study Start:2024-12-01

Study Completion:2026-12-31

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06578429

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:25 Years to 75 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
Age 18 years or older Willing and able to provide informed consent Able to understand and follow study procedures Stable medical condition	* Transcranial magnetic stimulation (TMS) and magnetic resonance imaging (MRI) contraindications: such as a cardiac pacemaker, cochlear implant, or an implanted device (deep brain stimulation, ferromagnetic metal in the head and body, claustrophobia, pregnant or breastfeeding or other ferromagnetic device/object in the head and body within 30 cm of the treatment coil. * General medical condition, disease, or neurological disorder that interferes with the assessments or participation. * Unable to safely withdraw, at least two weeks prior to treatment, from medications that increase seizure risk. * Current substance abuse as determined by positive toxicology screen * Have a mass lesion, cerebral infarct, or other active CNS disease, including a seizure disorder. * A recent suicide attempt (defined as within the last 30 days) or presence of current suicidal plan or intent. Patients at risk for suicide will be required to establish a written safety plan involving their primary therapist before entering the study. * Severe impediment to vision, hearing and/or hand movement, as this is likely to interfere with the ability to follow study protocols. * Greater than mild traumatic brain injury (defined as greater than 10 minutes loss of consciousness). * Taking benzodiazepines or neuroleptic medications, or any medication known to alter seizure threshold. * Acute or unstable chronic illness. * Current or lifetime history of bipolar disorder or psychosis. * Participation in another concurrent intervention-based clinical trial.

Inclusion Criteria

Exclusion Criteria

Age 18 years or older
Willing and able to provide informed consent
Able to understand and follow study procedures
Stable medical condition

* Transcranial magnetic stimulation (TMS) and magnetic resonance imaging (MRI) contraindications: such as a cardiac pacemaker, cochlear implant, or an implanted device (deep brain stimulation, ferromagnetic metal in the head and body, claustrophobia, pregnant or breastfeeding or other ferromagnetic device/object in the head and body within 30 cm of the treatment coil.
* General medical condition, disease, or neurological disorder that interferes with the assessments or participation.
* Unable to safely withdraw, at least two weeks prior to treatment, from medications that increase seizure risk.
* Current substance abuse as determined by positive toxicology screen
* Have a mass lesion, cerebral infarct, or other active CNS disease, including a seizure disorder.
* A recent suicide attempt (defined as within the last 30 days) or presence of current suicidal plan or intent. Patients at risk for suicide will be required to establish a written safety plan involving their primary therapist before entering the study.
* Severe impediment to vision, hearing and/or hand movement, as this is likely to interfere with the ability to follow study protocols.
* Greater than mild traumatic brain injury (defined as greater than 10 minutes loss of consciousness).
* Taking benzodiazepines or neuroleptic medications, or any medication known to alter seizure threshold.
* Acute or unstable chronic illness.
* Current or lifetime history of bipolar disorder or psychosis.
* Participation in another concurrent intervention-based clinical trial.

Contacts and Locations

Study Contact

Samantha Ward, BS

CONTACT

650-493-5000

samward@stanford.edu

Eileen G Fischer, BS

CONTACT

210-993-2065

grace.fischer@stanford.edu

Principal Investigator

Claudia B Padula, PhD

PRINCIPAL_INVESTIGATOR

Stanford University

Michelle R Madore, PhD

PRINCIPAL_INVESTIGATOR

Stanford University

Study Locations (Sites)

VA Palo Alto Health Care System

Palo Alto, California, 94304

United States

Collaborators and Investigators

Sponsor: Stanford University

Claudia B Padula, PhD, PRINCIPAL_INVESTIGATOR, Stanford University
Michelle R Madore, PhD, PRINCIPAL_INVESTIGATOR, Stanford University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-12-01

Study Completion Date2026-12-31

Study Record Updates

Study Start Date2024-12-01

Study Completion Date2026-12-31

Terms related to this study

Keywords Provided by Researchers

Veterans
Deep Transcranial Magnetic Stimulation (dTMS)
Neuroimaging
Relapse

Additional Relevant MeSH Terms

Methamphetamine Use Disorder
Transcranial Magnetic Stimulation